Classics in Chemical Neuroscience: Clozapine
†Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600, United States
‡Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
§Vanderbilt Center for Neuroscience Drug Discovery, Nashville, Tennessee 37232-6600, United States
Author information ►Article notes ►Copyright and License information ►
Received 2013 Jun 6; Accepted 2013 Jun 6.
Copyright © 2013 American Chemical Society
ACS Chem Neurosci. 2013 Jul 17; 4(7): 1018–1025.
Published online 2013 Jul 17. doi: 10.1021/cn400121z
This article has been cited by other articles in PMC.
Clozapine was the first true breakthrough in schizophrenia treatment since the discovery of chlorpromazine in 1950, effectively treating positive, negative, and some cognitive symptoms, as well as possessing unprecedented efficacy in treatment-resistant patients. Despite over 30 years of intense study, the precise molecular underpinnings that account for clozapine’s unique efficacy remain elusive. In this Viewpoint, we will showcase the history and importance of clozapine to neuroscience in general, as well as for the treatment of schizophrenia, and review the synthesis, pharmacology, drug metabolism, and adverse events of clozapine.
Keywords: clozapine, N-desmethylclozapine, schizophrenia, pharmacology
Schizophrenia is a complex, heterogeneous neuropsychiatric disorder composed of positive, negative and cognitive symptom domains with a prevalence of approximately 1% worldwide.1−6 Prior to the 1950s, treatment for schizophrenic patients focused on institutionalization (typically with heavy sedation) or electroconvulsive therapy.1 Major milestones in the pharmacotherapy of schizophrenia occurred first in the 1950s, with the discovery of chlorpromazine (1) and haloperidol (2), so-called typical or first generation antipsychotics (FGAs),1−6 followed in the 1970s by the development of clozapine (3), the first atypical or second generation antipsychotic (SGAs),7−14 an advance that regained momentum in 1989 following reintroduction of clozapine to the market by the United States Food and Drug Administration (FDA) (Figure 1).9,12−14 Chlorpromazine (1) and haloperidol (2), both potent D2 antagonists, led to the development of the dopamine hypothesis of schizophrenia.6,7,15,16 This model proposes that imbalances in dopamine transmission induce the presentation of particular symptomatic domains (i.e., hyperactivity in subcortical mesolimbic projections leads to positive symptoms and hypoactivity in mesocortical projections to the prefrontal cortex leads to negative symptoms and cognitive impairment).6,7,15,16 Early data correlating clinical efficacy with D2 potency provided credence to this hypothesis. However, the FGAs led to extrapyramidal side effects (EPS) via their actions at D2 (muscle rigidity, tremors, Parkinsonian-like symptoms), which resulted in poor patient compliance.6,7,15,16 Clozapine (3) was the first antipsychotic agent that dissociated clinical efficacy for positive symptoms from the risk of developing EPS, and 42 years later clozapine remains the one of the most clinically effective antipsychotics available, despite the development of numerous, structurally related SGAs and even third generation antipsychotics (TGAs).1,7−14 Imaging studies suggest that while FGAs require striatal D2 occupancy of ∼75% for efficacy (and EPS occur at ∼80% occupancy), SGAs, such as 3, display <60% occupancy of striatal D2 receptors.13,14,17,18 Thus, D2 inhibition alone cannot account for the efficacy of 3. As will be detailed later in this Viewpoint, 3 is a preeminent example of serendipitous polypharmacology. In addition to D2, clozapine has high affinity for the serotonin 5-HT2A receptors, which led Janssen and Meltzer to propose a “dopamine-serotonin antagonism theory” wherein a high ratio of 5-HT2A inhibition to D2 inhibition accounts for the efficacy of atypical antipsychotics.19,20 More recently the so-called N-methyl-d-aspartate (NMDA) receptor hypofunction hypothesis has been advanced, which invokes circuit level dysfunction, particularly in glutamatergic circuitry, as a complementary hypothesis to describe the etiology of schizophrenia.21−25 Clozapine’s efficacy can be encapsulated under this hypothesis as well. Clozapine is a modest inhibitor of SNAT2, which increases synaptic glycine levels, thus activating NMDA receptors.26 In addition, the major circulating metabolite of 3, N-desmethylclozapine or NDMC (4), is an M1 allosteric agonist, which has been shown to potentiate NMDA receptor currents.27−29 Finally, there is also the cholinergic hypothesis of schizophrenia, where muscarinic agonism is desirable, and could potentially account for the improved efficacy of 3 and 4 on negative and cognitive symptoms in addition to the positive symptoms.30−32 Recent positive schizophrenia trial data with xanomeline, an M1/M4 preferring agonist, further adds credence to the therapeutic role of 4 in the overall effectiveness of 3.33 Thus, the observed clinical efficacy of clozapine can be accounted for under any and/or all of the prevailing hypotheses used to explain the etiology of schizophrenia.
Breakthrough medications for schizophrenia. Structures of the FGAs chlorpromazine (1) and haloperidol (2), and the SGA clozapine (3) and its major active metabolite N-desmethylclozapine (4).
However, clozapine is not a panacea. Indeed, clozapine was once pulled from the market due to the risk of severe adverse events, only to be later introduced, as it was shown to be the most effective agent available for therapy in treatment-resistant schizophrenics.7−14 Interestingly, it later also received labeling for effectively reducing recurrent suicidal behavior in patients with schizophrenia.12−14,34 Patients must be now carefully monitored and the dose of clozapine must be titrated to avoid potentially fatal toxicity.12−14,35 Thus, there is still an urgent and unmet medical need for more effective antipsychotic agents, and despite the structural similarity to 3 other SGAs such as olanzapine (5), quetiapine (6), and loxapine (7) have not proven to be as effective, nor have TGAs such as aripiprazole (8) and risperidone (9) (Figure 2).7−14
Structures of closely related SGAs 5–7 to clozapine and newer TGAs 8 and 9.
In this Viewpoint, we will review the synthesis, pharmacology, drug metabolism, and adverse events of 3. We will also showcase the history and importance of 3 to neuroscience in general, as well as for the treatment of schizophrenia. While there are several excellent reviews on certain aspects of clozapine,12−14 the aim of this Viewpoint was to capture all the relevant data and compile it in an easily accessible format.
Clozapine (CAS No. [5786-21-0]) is a low molecular weight tricyclic benzodiazepine (MW = 326.13) with a lone hydrogen bond donor, three hydrogen bond acceptors, and a cLogP of 3.7. Thus, clozapine conforms to Lipinski’s rules and displays excellent DMPK parameters and CNS penetration (vide infra). Originally developed by Sandoz (now Novartis), several variants of the synthesis of the benzodiazepine-based clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-benzo[b,e][1,4]diazepine, 3) were reported in late 1960s, and in the issued patent U.S. 3,539,573 published in 1970.36,37 These routes, and subsequent routes developed for analogue synthesis, first accessed the key 8-chloro-5H-benzo[b,e][1,4]diazepin-11(10H)-one core 14 (Scheme 1). In the original reports, halogenated nitro arene 10 is subjected to an Ullmann coupling the presence of 2-aminobenzoic acid 11 to afford disubstituted aniline 12. Reduction of the nitro moiety followed by refluxing in xylenes generates the key benzodiazepine core 14. Treatment with POCl3 provides the chloro imine derivative 15, which is then treated with N-methylpiperazine to deliver clozapine 3.36,37 Other variations have been reported.38,39 For example, the original patent also describes coupling N-methylpiperazine to 13 to generate the corresponding amide prior to thermal condensation leading to 3 directly. En route to a tritiated version of 3, de Paulis and co-workers39 first converted 14 to the thioamide, followed by methylation to provide an alternate leaving group for displacement by the tritiated N-methylpiperazine. In general, all the chemistries reported to access 3 and related analogues follow very similar synthetic routes.
Synthesis of Clozapine 3 Reported in Both the Primary and Patent Literature
Clozapine is the generic name of the drug 3, which is manufactured by Novartis (formerly Sandoz) under brand name Clozaril (other brand names employed for clozapine: FazaClo, Clopine, CloZAPine Synthon, Denzapine, Zaponex).40,41 Clozapine was first synthesized in the 1960s, launched in Europe in 1971, voluntarily withdrawn in 1975, and reapproved by the FDA in 1989. Novartis sells clozapine in 25 mg and 100 mg tablets. There are also three generic manufacturers of 25 mg and 100 mg bioequivalent clozapine: Caraco (approved 2002), Teva (approved 1997), and Mylan (approved 1999). While sales figures for clozapine are difficult to ascertain precisely, worldwide sales are estimated to exceed U.S. $200 million.12−14,40,41
Clozapine is a well-distributed CNS-penetrant compound that is 90–95% absorbed when administered orally without food).12−14,40,41 However, due to a high first pass effect, the absolute oral bioavailability is only moderate (F = 0.5–0.6). Clozapine displays low binding to plasma proteins (Fu = 0.05) and peak plasma levels are achieved about2 h after oral dosing. The elimination of clozapine is biphasic, with a terminal half-life of approximately 12 h after steady state has been achieved (typically 7 days of dosing). Moreover, clozapine is extensively metabolized by CYP450 enzymes (especially 1A2 and 3A4), resulting in 80% of the dose excreted as metabolites in the urine (50%) and feces (30%).12−14,40,41 These metabolites, 4 and 16–29, have been rigorously characterized (Figure 3).42−45 The vast majority of the metabolites are inactive, but the N-desmethyl metabolite 4, NDMC, is active (vide infra) and can account for 10–90% of the circulating dose of administered clozapine.12−14,28,28,46−49 The role of 1A2 in the metabolism of clozapine has been well characterized.12−14 Agents that induce 1A2, such as cigarette smoke, increase the rate of clozapine’s metabolism. Given the high incidence of cigarette smoking in the schizophrenic patient population, this can have a significant impact on medication management; smokers require increased dosage to maintain necessary plasma concentrations. Conversely, agents that inhibit 1A2, such as ciprofloxacin, decrease the metabolism of clozapine.12−14,42−45 Overall, the ratio of 3 to 4 varies across patients, with female and elderly populations exhibiting the greatest variability. The impact of the ratio of 3:4 on efficacy will be discussed in the pharmacology section, but careful monitoring of plasma levels of both 3 and 4 are used to assess metabolism, compliance, and to adjust dosage.12−14,40−49 In addition, the major toxicity that initiated the recall in 1975, agranulocytosis (vide infra), has been attributed to a reactive nitrenium ion 17 generated in neutrophils by myeloperoxidase (MPO) that leads to covalent modification.42−44
Structures of oxidative metabolites of clozapine 3, and subsequent conjugative phase II metabolites.42−45 The N-desmethyl metabolite 4 and the N-oxide 16 are the major metabolites, with 4 being active.
Pharmacology, Adverse Events, and Dosage
Without question, clozapine is the preeminent example of polypharmacology; more positively stated, clozapine is a broad spectrum ligand (Table 1).12−14 Because 4 is an active metabolite, the mode of action becomes further complicated in vivo. As such, there is a great deal of controversy, regarding clozapine’s unique efficacy and profile.12−14 While clozapine is a D2 antagonist, at therapeutic concentrations it occupies only 40–60% of D2 receptors; in contrast, FGAs occupy >80% of D2 receptors, which may account for the lack of extrapyramidal side effects with 3.13,14,17,18 This mild D2 activity coupled with a broad spectrum of cholinergic, adrenergic, and serotonergic activity may give rise to the unique efficacy profile. Others argue that the preference for either D1 or D4 inhibition over D2 is essential.50 In addition to D2, clozapine has high affinity for the serotonin 5-HT2A receptors.51 Beyond modulation of specific receptors, clozapine (3) and NDMC (4) have significant effects on GABA-ergic and glutamatergic circuitry.12−14,52 Clozapine is a modest inhibitor of SNAT2, which increases synaptic glycine levels, thus activating NMDA receptors.26 In addition, the major circulating metabolite of 3, N-desmethylclozapine or NDMC, (4), is an M1 allosteric partial agonist (EC50 = 115 nM), which has been shown to potentiate NMDA receptor currents.28−32 The efficacy of clozapine can be then partially attributed to 4, which also possess D2 and 5-HT2A activity comparable to 3 (Table 1),53 and it is likely this combination of activity through modulation of glutamatergic and muscarinic neurotransmission, as well as numerous biogenic amines, that sets clozapine apart as a clinically effective treatment for treatment-resistant schizophrenia.12−14,28−32 Intriguingly, a recent study raised concern over the classification of 4 as an M1 agonist. In human brain tissue from post-mortem schizophrenic patients, a GTPγS assay showed that 4 was an M1 antagonist.54 However, we and others have recently shown that M1 partial agonists display brain-region specific pharmacology (agonism/antagonism) based on receptor reserve.55−57 GTPγS assays have no receptor reserve, and under these conditions partial agonists would behave as antagonists; thus, this potentially contradictory result can be explained. The role of 4 in the efficacy of clozapine therapy has been addressed in a clinical guideline, calling for consideration of the ratio of 3:4.12−14,28−32 While numerous accounts over the past 30 years have reported pharmacologic data for 3 and 4, variability in assays and cell lines preclude a true head-to-head comparison; therefore, we elected to show data (Table 1) from the NIMH Psychoactive Drug Screening Program where cell lines and assay protocols are consistent.53
Pharmacological Profiles of Clozapine (3) and N-Desmethylclozapine (4)53a
A number of adverse events, ranging from relatively minor to fatal, have been reported with clozapine.12−14,40,41,58,59 Among the most serious of these is agranulocytosis (vide infra), which led to the recall of clozapine in 1975. Overall, clozapine has five black box warnings (agranulocytosis, seizures, myocarditis, other adverse cardiovascular and respiratory effects, and increased mortality in elderly patients with dementia-related psychosis). Beyond this, hypotension, tachycardia, sedation/drowsiness, vertigo, bone marrow suppression, and rebound psychosis have been reported.12−14,40,41,58,59 Another serious issue with clozapine is weight gain (typically a ≥7% increase in body weight over the first 6 months of therapy), which places patients at increased risk for diabetes and cardiovascular disease. Studies have shown that clozapine disrupts metabolism such that the body derives increased energy from fat versus carbohydrates, resulting in high carbohydrate levels that can ultimately lead to insulin resistance and diabetes. Other adverse events include urinary incontinence, withdrawal effects, hypersalivation (“wet pillow syndrome”), gastrointestinal hypomotility (severe constipation), and elevation of liver enzymes (typically around 10%). However, unlike the FGAs, clozapine has a low incidence of EPS and no effect on prolactin levels.12−14,40,41,58,59
Due to the risk of agranulocytosis, patients must have a blood test prior the initiation of clozapine therapy, and must have their white blood cell counts (WBC) and absolute neutrophil counts (ANC) monitored during their course of treatment and for 4 weeks after treatment ends.12−14,40,41,58,59 To qualify for clozapine treatment, counts must be within normal range ((WBC ≥ 3500/mm3 (3.5 × 109/L) and ANC ≥ 2000/mm3 (2.0 × 109/L)). Qualifying patients initiate therapy with one to two 12.5 mg doses orally on day one, followed by one to two 25 mg oral doses on day two. If tolerated, the dose can be escalated over 2–3 weeks in 25 to 50 mg increments until a 300 mg/day dose is achieved. For the majority of patients, antipsychotic efficacy is noted between 200 to 450 mg/day, typically divided unequally with the largest portion being administered at bedtime. If required, the dose can be further increased in increments of 50 to 100 mg. The maximum dose allowed is 900 mg/day, but adverse events grow increasingly common at doses exceeding 450 mg/day. When clozapine therapy is ended, a gradual reduction in dose over a one to two week period is recommended, as abrupt cessation can lead to withdrawal symptoms.12−14,40,41,58,59
History and Importance in Neuroscience
Imagine a time when the standard of care for patients with schizophrenia is institutionalization (typically with heavy sedation) or electroconvulsive therapy.1 Then, in the 1950s, small molecule therapeutics appear, initially as a panacea, with chlorpromazine (1) and haloperidol (2) reducing psychotic (or positive symptoms) of schizophrenia. However, these FGAs induce EPS and Parkisonsonian-like motor disturbances, due to their potent D2 inhibition.1−6 Still, their introduction is a landmark in schizophrenia care, despite the side effect profiles and lack of efficacy on the negative symptoms and cognitive deficits, which are key determinants of long-term disability and treatment outcome.1−6 Furthermore, 30–70% of schizophrenic patients are nonresponsive to these agents for remission of positive symptoms, and are considered to have treatment-resistant schizophrenia (schizophrenia patients that despite at least two adequate trials of standard neuroleptic drugs, have persistent moderate-to-severe positive symptoms, disorganization or negative symptoms, together with poor social and work function over a prolonged period of time).1−14
Clozapine (3) enters the scene in Europe in 1971 as the first agent to dissociate antipsychotic efficacy from EPS and other motor side effects, a major landmark in the treatment of schizophrenia that paves the way for other SGAs and TGAs.1−14 Moreover, clozapine is eventually found to be effective on negative symptoms as well as improving certain domains of cognitive function (memory, verbal learning, verbal fluency, and psychomotor speed) but not others (executive function and working memory). Needless to say, psychiatrists are thrilled with the prospects of clozapine in managing the multisymptom domains of their schizophrenic patients. The momentum comes to a screeching halt in 1975 based on reports from Finland, where 16 patients out of 2206 (0.7%) developed agranulocytoisis, an acute condition resulting in lowered white blood cell count(commonly neutrophils), placing patients at high risk of infections due to suppressed immune systems. Of the 16 patients, 8 (50%) developed secondary infections and died; however, no other clustering of agranulocytoisis was reported in Finland or in any other countries. Still, Sandoz voluntarily withdrew clozapine from the market in Europe and ongoing clinical trials elsewhere in the world were suspended.1−14
During the ensuing years after the withdrawal, many European patients that had responded well to clozapine relapse failed to respond to any of the available antipsychotic drugs. Thus, under pressure from this patient group, administration of clozapine is permitted on a restricted basis. Studies then show that clozapine is effective in treatment-resistant schizophrenia, improving positive symptoms as well as tardive dyskinesia (a motor disorder resulting in involuntary, repetitive body movements), again distinguishing itself from classical FGAs and newer SGAs.1−14 Due to a lack of new, effective agents, in 1989, Sandoz seeks approval from the FDA for clozapine in patients with treatment-resistant schizophrenia, and wins approval. All regulatory agencies worldwide, including the FDA, require blood testing for patients taking clozapine, to monitor for the development of agranulocytoisis. Typically, the risk of agranulocytoisis decreases 10-fold over the first six months, and with monitoring, incidence has now dropped to 0.38%. Multiple trials validate the efficacy of clozapine on treatment resistant schizophrenics, with around 30% showing improved Brief Psychiatric Rating Scale scores after 6 weeks of treatment, and nearly 70% show improvement after 6 months of treatment.1−14 Later, clozapine also shows efficacy in adolescents with treatment-resistant schizophrenia. Comparable efficacy is noted for the treatment negative symptoms, though the impact on cognitive deficits is not as clear (possibly owing to the variability in the metabolism of 3 and concentration of 4).1−14
Over the intervening years, it is recognized that yet another unmet medical need in this patient population is an elevated mortality rate. Recent data indicate that people with schizophrenia have a higher incidence of suicide, with a lifetime attempt rate of about 60% and a completed suicide rate of 9–13%.1−14 Suicide rates are seen to be higher in males and in the early stages of the disease. In several trials, clozapine is shown to significantly reduce the rate of suicide attempts by as much as 88% when compared to FGAs and other SGAs. A retrospective analysis of the 100 000 patient Clozaril trial reveals a suicide rate 25–50% lower than expected.1−14 These data led the FDA to approve clozapine in 2002 for reducing the risk of recurrent suicidal behavior in patients with schizophrenia. Overall, clozapine is shown to offer numerous advantages over other SGAs and TGAs even today (Table 2).1−14
A final issue often associated with clozapine therapy centers on the cost-effectiveness, for which there have been numerous studies and with diverse outcomes.12,14 Estimated costs for a typical patient (300–400 mg/day of clozapine) coupled with blood monitoring is ∼$5500/year, a figure almost 11-times greater than other conventional SGAs.12,14,60 However, some feel that the added expense of clozapine treatment is offset by the corresponding reduction in hospital costs and crisis care, often required for aggressive and/or treatment-resistant schizophrenics. Indeed, Meltzer found that clozapine therapy reduced direct costs associated with treatment-resistant schizophrenics by ∼50% per year.15 Other studies find variable savings; however, it is hard to estimate the cost borne by families and caregivers, lost wages, and so forth. Clearly, the ability of treatment-resistant patients to return to productive lives and jobs, freeing family members to return to work, further factors in to the cost savings realized by clozapine treatment.12,14,60
In summary, despite turning 42 this year, clozapine remains one of the most uniformly effective antipsychotic agents available, despite its significant adverse event profile, including five black box warnings (worst side effect profile of any antipsychotic). Clozapine was the first true breakthrough in schizophrenia treatment since the discovery of chlorpromazine in 1950, and it effectively treats positive, negative, and some cognitive symptoms. Moreover, clozapine is effective in treatment-resistant patients and has been shown to reduce the risk of suicide. Despite over 30 years of intense study, the precise molecular underpinnings that account for clozapine’s unique efficacy remain elusive. Perhaps the ability of clozapine and its major metabolite NDMC to modulate biogenic amines and complex glutamatergic, GABAergic, and cholingergic circuitry serendipitously strikes the right balance of activities needed to treat the diverse, heterogeneous patient population present in schizophrenia. Many clinicians feel that clozapine is under-prescribed, and it is estimated that only 14–50% of clozapine-eligible patients are on the medication. Furthermore, there is a clear decline in the use of clozapine, despite the overwhelming benefits for unmet medical need in this patient population, and this trend is thought to be driven by aggressive marketing of current SGAs and TGAs.12,14,61 Unfortunately, this may lead to a new generation of clinicians unfamiliar with prescribing, managing, and monitoring clozapine, leading to less than optimal care for treatment-resistant schizophrenics that may result in more hospitalization.14,61 For fundamentally changing the standard of care in patients with schizophrenia and remaining an important, frontline therapy for over 40 years, we firmly believe that clozapine represents a classic in chemical neuroscience.
The authors declare no competing financial interest.
- Weinberger D. R., and Harrison P. J., Eds., (2011) Schizophrenia, 3rd ed., Wiley-Blackwell Publishing, Ltd., Oxford, UK.
- Carlsson A.; Lindquist M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normethanephrine in mouse brain. Acta Pharmacol. Toxicol.20, 140–144. [PubMed]
- Andreasen N. C. (2000) Schizophrenia: the fundamental questions. Brain Res. Rev.31, 106–112. [PubMed]
- Karayiorgou M. (2001) Genetic aspects of schizophrenia. Clin. Neurosci. Res.1, 158–163.
- Seeman P.; Lee T.; Chau-Wong M.; Wong K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature261, 717–719. [PubMed]
- Seeman P.; Lee T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science188, 1217–1219. [PubMed]
- Burns M. J. (2001) The pharmacology and toxicology of atypical antipsychotic agents. Clin. Toxicol.39, 1–14. [PubMed]
- Breier A.; Buchanan R. W.; Kirkpatrick B.; David O. R.; Irish D.; Summerfelt A.; Carpenter J. W. Jr. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry151, 20–26. [PubMed]
- Kane J.; Honigfeld G.; Singer J.; Meltzer H. Y. (1988) Clorazil Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45, 789–796. [PubMed]
- Buchanan R. W.; Breier A.; Kirkpatrick B.; Ball P.; Carpenter J. W. Jr. (1988) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry151, 755–760. [PubMed]
- Chakos M.; Lieberman J.; Hoffman E.; Bradford D.; Sheitman B. (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry158, 518–526. [PubMed]
- Meltzer H. Y. (1997) Treatment-resistant schizophrenia – The role of clozapine. Curr. Med. Res. Opin.14, 1–20. [PubMed]
- Naheed M.; Green B. (2001) Focus on clozapine. Curr. Med. Res. Opin.17, 223–229. [PubMed]
- Fakra E.; Azorin J.-M. (2012) Clozapine for the treatment of schizophrenia. Expert Opin. Pharmacother.13, 1923–1935. [PubMed]
- Meltzer H. Y.; Stahl S. M. (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull.2, 19–76. [PubMed]
- Creese I.; Burr D. R.; Synder S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science19, 481–483. [PubMed]
- Coward D. M. (1992) General pharmacology of clozapine. Br. J. Psychiatry160, 5–11. [PubMed]
- Kapur S.; Seeman P. (2000) Does fast dissociation from the dopamine (d2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry57, 553–559. [PubMed]
- Meltzer H. Y.; Matsubara S.; Lee J. C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of D1, D2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther.251, 238–246. [PubMed]
- Janssen P. A.; Niemegeers C. J.; Awouters F.; Schellenkens K. H.; Megens A. A.; Meert T. F. (1988) Pharmaoclgoy of risperidone (R 64776), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonisitc properties. J. Pharmacol. Exp. Ther.244, 685–693. [PubMed]
- Olney J. W.; Newcomer J. W.; Farber N. B. (1999) NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res.33, 523–533. [PubMed]
- Lindsley C. W.; Shipe W. D.; Wolkenberg S. E.; Theberge C. R.; Williams D. L. Jr.; Sur C.; Kinney G. G. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem.8, 771–784. [PubMed]
- Menniti F. S.; Lindsley C. W.; Conn P. J.; Pandit J.; Zagouras P.; Volkmann R. A. (2013) Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic networks. Curr. Top. Med. Chem.13, 26–54. [PubMed]
- Moghaddam B.; Javitt D. (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implications for treatment. Neuropsychopharmacol. Rev.37, 4–15. [PMC free article][PubMed]
- Conn P. J.; Tamminga C.; Schoepp D. D.; Lindsley C. (2008) Schizophrenia: Moving Beyond Monoamine Antagonists. Mol. Interventions8, 99–105. [PubMed]
- Javitt D. C.; Duncan L.; Balla A.; Sershen H. (2005) Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanism of action. Mol. Psychiatry10, 276–286. [PubMed]
- Marino M. J.; Rouse S. T.; Levey A. I.; Potter L. T. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. U.S.A.95, 11465–11470. [PubMed]
- Sur C.; Mallorga P. J.; Wittman M.; Jacobson M. A.; Pascarella D.; Williams J. B.; Brandish P. E.; Pettibone D. J.; Scolnick E. M.; Conn P. J. (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. U.S.A.100, 13674–13679. [PubMed]
- Li Z.; Huang M.; Ichikawa J.; Dai J.; Meltzer H. Y. (2005) N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology30, 1986–1995. [PubMed]
- Marino P. J.; Conn P. J. (2002) Direct and indirect modulation of the N-methyl-d-Aspartate receptor: potential for the development of novel antipsychotic therapies. Curr. Drug Targets: CNS Neurol. Disord.1, 1–16. [PubMed]
- Bridges T. M.; LeBois E. P.; Hopkins C. R.; Wood M. R.; Jones J. K.; Conn P. J.; Lindsley C. W. (2010) Antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect.23, 229–240. [PubMed]
- Shannon H. E.; Rasmussen K.; Bymaster F. P.; Hart J. C.; Peters S. C.; Swedberg M. D.; Jeppesen L.; Sheardown M. J.; Sauerberg P.; Fink-Jensen A. (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res.42, 249–259. [PubMed]
- Shekhar A.; Potter W. Z.; Lightfoot J.; Lienemann J.; Dube S.; Mallinckrodt C.; Bymaster F. P.; McKinzie D. L.; Felder C. C. (2008) Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. Am. J. Psychiatry165, 1033–1039. [PubMed]
- “Supplimental NDA Approval Letter for Clozaril, NDA 19-758/S-047”. United States Food and Drug Administration. December 18, 2002. Archived from the original on June 3, 2013.
- Cohen D.; Bogers J. P.; van Dijk D.; Bakker B.; Schulte P. F. (2012) Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J. Clin. Psychiatry73, 1307–1310. [PubMed]
- Schmutz J., and Hunziker F. (1970) 11-Basic substituted dibenzodiazepines and dibenzothiazepines. US 3,539,573.
- Hunziker F.; Fischer E.; Schmutz J. (1967) 11-Amino-5H-dibenzo[b,e]-1,4-diazepine. Helv. Chim. Acta50, 1588–1599.
- Liao Y.; Venhuis B. J.; Rodenhuis N.; Timmerman W.; Wikstrom H. (1999) New (sulfonyloxy)piperazinylbibenzadiazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation. J. Med. Chem.42, 2235–2244. [PubMed]
- de Paulis T.; Davis D. A.; Smith H. E. (1988) Synthesis of [3H]clozapine. J. Labeled Comp. Pharm.25, 1027–1033.
- For information on clozapine (clorazil), see www.Novartis.com.
- For information on clozapine (clorazil), see www.clorazil.com
- Sikora A.; Adamus J.; Marcinek A. (2007) Disproportionation of clozapine radical: A link between one-electron oxidation and formation of it nitrenium cation. Chem. Res. Toxicol.20, 1093–1098. [PubMed]
- Dragovic S.; Boerma J. S.; van Bergen L.; Vermeulen N. P. E.; Commandeur J. N. M. (2010) Role of glutathione S-transferase in the inactivation of reactive metabolites of clozapine. Chem. Res. Toxicol.23, 1467–1476. [PubMed]
- Gardener I.; Popovic M.; Zahid N.; Uetrecht J. P. (2005) A comparison of the covalent binding of clozapine, procainamide and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem. Res. Toxicol.18, 1384–1394. [PubMed]
- Dain J. G.; Nicoletti J.; Ballard F. (1997) Biotransformations of clozapine in humans. Drug Metab. Dispos.25, 603–609. [PubMed]
- Wiebelhaus J. M.; Vunck S. A.; Meltzer H. Y.; Porter J. H. (2012) Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice. Behav. Pharmacol.23, 262–270. [PubMed]
- Cremers T. I. F.; Flik G.; Hofland C.; Stratford R. E. Jr. (2012) Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug Metab. Dispos.40, 1909–1916. [PubMed]
- Heusler P.; Slot L. B.; Tourette A.; Tardif S.; Cussac D. (2011) The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human D2 and serotonin 5-HT1A receptors. Eur. J. Pharmacol.669, 51–58. [PubMed]
- Maehara S.; Okuda S.; Ohta H. (2011) Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Res. Bull.86, 146–151. [PubMed]
- Seeman P.; Corbett R.; van Toll H. H. (1997) Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmaoclogy16, 93–110. [PubMed]
- Meltzer H. Y. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmaoclogy21, 106S–115S. [PubMed]
- Natesan S.; Reckless G. E.; Barlow K. B. L.; Nobrega J. N.; Kapur S. (2007) Evaluation of N-desmethylclozapine as a potential antipsychotic – preclinical studies. Neuropsychopharmaoclogy32, 1540–1549. [PubMed]
- [Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate] was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD.
- Thomas D. R.; Dada A.; Jones G. A.; Deisz R. A.; Gigout S.; Langmead C. J.; Werry T. D.; Hendry N.; Hagan J. J.; Davies C. H.; Watson J. M. (2010) N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology58, 1206–1214. [PubMed]
- Lebois E. P.; Bridges T. M.; Dawson E. S.; Kennedy J. P.; Xiang Z.; Jadhav S. B.; Yin H.; Meiler J.; Jones C. K.; Conn P. J.; Weaver C. D.; Lindsley C. W. (2010) Discovery and development of novel subtype-selective M1 allosteric agonists for the investigation of M1 receptor function. ACS Chem. Neurosci.1, 104–121. [PubMed]
- Digby G. J.; Noetzel M. J.; Bubser M.; Utley T. J.; Walker A. G.; Byun N. B.; LeBois E. P.; Xiang Z.; Sheffler D. J.; Niswender C. M.; Plumley H. C.; Davis A. A.; Nemirovsky N. E.; Mennenga S.; Camp B. W.; Bimonte-Nelson H. A.; Morrison R.; Daniels S.; Lindsley C. W.; Olive M. F.; Conn P. J. (2012) Novel allosteric agonists of the M1 muscarinic acetylcholine receptor induce brain region-specific responses and correspond with behavioral effects in animal models. J. Neurosci.32, 8532–8544. [PubMed]
- Digby G. J.; Utley T. J.; Lamsal A.; Sevel C.; Sheffler D. J.; Lebois E. P.; Bridges T. M.; Wood M. R.; Niswender C. M.; Lindsley C. W.; Conn P. J. (2012) Chemical modification of the M1 agonist VU0364572 reveals molecular switches in pharmacology as well as a bitopic binding mode. ACS Chem. Neurosci.3, 1025–1036. [PubMed]
- Flanagan R. J. (2008) Sides effects of clozapine and some other psychoactive drugs. Curr. Drug Saf.3, 115–122. [PubMed]
- Burns M. J. (2001) The pharmacology and toxicology of atypical antipsychotic agents. Clin. Toxicol.39, 1–14. [PubMed]
- Meltzer H. Y.; Cola P. A. (1994) The pharmacoecomonics of clozapine: a review. J. Clin. Psychiatry55(Suppl. B), 161–165. [PubMed]
- Kelly D. L.; Buchanan R. W. (2007) Why not clozapine?. Clin. Schizophr. Relat. Psychoses1, 92–95.
Articles from ACS Chemical Neuroscience are provided here courtesy of American Chemical Society
Nearly half a century after it was introduced, the first atypical antipsychotic drug clozapine (Clozaril) has yet to reach its full potential. In the early 1970s, many psychiatrists questioned whether it could even be a neuroleptic agent because of its lack of extrapyramidal side effects.
But the subsequent development of a series of second-generation antipsychotic agents, still widely referred to as “atypical” because of their lack of associated movement problems, helped dispel the notion that antipsychotic and extrapyramidal effects must always go together. However, the risk of agranulocytosis with clozapine and the need for regular prophylactic blood monitoring continues to limit the drug’s true potential in treatment-resistant schizophrenia.
“The first generation antipsychotics didn’t work for everybody and, when they did work, there were significant problems with Parkinson’s-like movement disorders and longer term tardive dyskinesia, often affecting the tongue and mouth. This sometimes made people look different and could be stigmatising, so the relative absence of movement side effects with clozapine and the other second-generation drugs was very welcome,” explains Fiona Gaughran, lead consultant psychiatrist, National Psychosis Service, South London and Maudsley (SLAM) NHS Foundation Trust, London.
“The joy of clozapine was that you could use it to treat people who didn’t respond to anything else — and really make a difference,” she adds.
Not just a dopamine blocker?
Why clozapine is more effective for treatment-resistant schizophrenia than other antipsychotic agents remains uncertain. For many years, clinicians have linked schizophrenia to increased dopamine synthesis in striatal tissue, and the efficacy of antipsychotic agents — first and second generation — appears related to their ability to block dopamine (D2) receptors. However, brain scanning research has suggested that patients with treatment-resistant schizophrenia may not have abnormal dopamine synthesis, so clozapine could be working through other mechanisms, one of which may be glutamate dysfunction.
“We are at a new phase of research, acknowledging that schizophrenia may result from more than one disease process. Most patients respond to dopamine blockers, but clozapine probably does something on top because it helps those patients who don’t respond to other agents,” points out Dr Gaughran.
Launch, withdrawal, reintroduction
Clozapine was synthesised and characterised by Swiss pharmaceutical company Wander (now part of Novartis) in 1956 — only six years after the first-generation drug, chlorpromazine, was discovered in the laboratories of Rhône-Poulenc (now part of Sanofi-Aventis) (PJ 2011;286:249).
In the mid-1960s, clozapine was one of three compounds that Wander offered to researchers in Berlin who were trying to establish the structural differences between tricyclic compounds that affected whether they were antidepressants or neuroleptics. According to the theory of the German team, the orientation of the tricyclic rings of the three compounds should have made them antidepressants. But clinical investigation showed that they had neuroleptic effects, and a new class of schizophrenia treatment was born.
After early clinical trials confirmed clozapine’s antipsychotic efficacy and lack of extrapyramidal side effects, the drug was gradually introduced across Europe during the early 1970s. However, when Finnish clinicians reported a cluster of cases of agranulocytosis in elderly and infirm patients treated with clozapine, resulting in seven deaths, the product was voluntarily withdrawn by Sandoz, which had merged with Wander in 1967.
Some psychiatrists did not want to lose clozapine because they had seen the benefits of treatment, particularly in those with tardive dyskinesia. Sandoz and the US Food and Drug Administration were therefore persuaded to set up a major comparative clinical trial of clozapine and chlorpromazine in patients who were refractory to at least three neuroleptic agents and had failed to respond to haloperidol = 60mg per day.
Of the 268 patients in the six-week study, 30 per cent of the clozapine-treated patients were categorised as responders compared with 4 per cent of chlorpromazine-treated patients. The improvement with clozapine included “negative” as well as “positive” symptoms and there were no cases of agranulocytosis.
“The result was clearly in favour of clozapine, and led to the drug being brought back, but in a highly regulated way, with patients having baseline and weekly blood tests for the first 18 weeks, followed by fortnightly tests until week 52, and monthly tests after that,” says Dr Gaughran.
Clozapine was reintroduced in 1990, and it was soon followed by other second-generation agents, such as risperidone and olanzapine, which have not been linked to neutropenia and agranulocytosis.
Traffic lights for clozapine monitoring
Dr Gaughran explains that many patients with schizophrenia are treated successfully with clozapine over a number of years. A “traffic light” system is used to differentiate between patients with modest falls in neutrophils who require repeat tests (amber), and those with more serious reductions where immediate treatment cessation is needed (red).
Some people of black African heritage naturally have lower neutrophil counts than those of Caucasian origin. This is known as benign ethnic neutropenia (BEN). The clozapine traffic light system can be adapted to allow for the lower baseline neutrophil and white cell counts once a formal diagnosis of BEN is confirmed by a haematologist.
Psychiatrists have drawn attention to the importance of BEN, so that black patients are not mistakenly believed to be ineligible for clozapine use because of a low baseline neutrophil count.
After someone has a red light on clozapine, there are significant risks associated with rechallenge, but this is sometimes possible. A systematic review showed that clozapine rechallenge was successful in 70 per cent of patients after neutropenia but only in 20 per cent if agranulocytosis had occurred. Dr Gaughran points out that, because a second drop in neutrophils while on clozapine tends to be deeper and longer lasting than a first fall, careful clinical risk-benefit analyses are required. Rechallenge is not recommended following agranulocytosis.
Clozapine is the only antipsychotic agent licensed for treatment-resistant schizophrenia, and National Institute for Health and Care Excellence recommends that it should be offered to patients who have not responded sufficiently to sequential use of adequate doses of at least two different antipsychotic drugs. At least one of these should be a non-clozapine second-generation antipsychotic.
However, there is evidence of continuing delays in starting treatment-resistant patients on clozapine. A review of records of 149 patients started on clozapine at SLAM NHS Foundation Trust between 2006 and 2010 estimated a four-year delay in getting patients on the drug. In about one-third of patients, there was evidence of polypharmacy or high-dose treatment before starting clozapine.
“Global rates of clozapine use in schizophrenia patients vary enormously from only about one in 20 in the US to around one-third in Finland. It’s clear that we aren’t yet treating everyone who could benefit from clozapine and much of this is due to concern about side effects and the practicalities of regular monitoring, especially during initiation,” says Dr Gaughran.
Balancing safety and efficacy
The risk of agranulocytosis, albeit low, is not the only reason why some clinicians are reluctant to prescribe clozapine to treatment-resistant patients with schizophrenia. Other side effects include weight gain, hypersalivation, constipation, tachycardia, dose-related reduction in seizure threshold, sedation and incontinence, although established management strategies are available for these potential side effects.
The impact of second-generation antipsychotic agents on risk factors for cardiovascular disease (CVD) such as obesity and diabetes has been a cause for concern. People with schizophrenia die 20–25 years earlier than the general population, and 60 per cent of the excess mortality is due to physical conditions, such CVD and pulmonary disease. However, research has shown that long-term use (7–11 years) of any antipsychotic treatment by people with schizophrenia is associated with lower mortality than no drug use and clozapine is associated with lower mortality than other commonly used first- and second-generation antipsychotic agents.
“People with schizophrenia, like the rest of us, need to be mentally well enough to manage their physical health. Effectively treating psychosis reduces disorganisation, allowing people to make choices regarding their lifestyle options and physical health,” says Dr Gaughran.
Neither she nor other psychiatrists advocate clozapine as first-line treatment for schizophrenia because there is no evidence of benefit over other antipsychotics in this group of patients. But Dr Gaughran suggests that, if people are resistant to two other antipsychotics, delays in moving onto clozapine can affect more than just their mental health. They can mean that patients become increasingly alienated and disenfranchised.
“We need to be less frightened of using clozapine where it’s indicated, and to get systems in place to monitor treatment initiation effectively. Treatment-resistant patients are much more likely to respond to clozapine than to another agent, and getting them onto something that works for them will help them get back into their social system and reduce the need for hospital admissions,” points out Dr Gaughran.
In south London, a home-treatment service for clozapine has been established that enables patients to have vital signs checked every day, along with their regular blood tests for neutropenia. The aim is to support patients through the early phase of treatment, pick up problems quickly, actively manage side effects and avoid the need for hospital admissions.
“We’ve spent 30 years looking for something better than clozapine for our treatment-resistant patients, but we still haven’t found anything to surpass it,” concludes Dr Gaughran. “We aren’t yet using it early enough in those who could benefit and we also need to work on individualising treatment. In that way, patients will get the lowest effective dose of clozapine, tolerate it better and will be happy to stay on it.”
Citation: The Pharmaceutical Journal, 18 January 2014, Vol 292, No 7793, p58 | DOI: 10.1211/PJ.2014.11132880